AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
cyproterone acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiandrogens | 766 | 427-51-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An agent with anti-androgen and progestational properties. It shows competitive binding with dihydrotestosterone at androgen receptor sites.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
| 0.10 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 10.28 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 100 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1974 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Meningioma | 1028.14 | 56.50 | 148 | 863 | 4923 | 90622513 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Meningioma | 564.60 | 41.67 | 82 | 721 | 1645 | 42618887 |
| Meningioma benign | 46.46 | 41.67 | 6 | 797 | 45 | 42620487 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Meningioma | 1422.49 | 38.67 | 208 | 1498 | 5457 | 110582136 |
| Meningioma benign | 58.72 | 38.67 | 9 | 1697 | 307 | 110587286 |
| Frontotemporal dementia | 45.09 | 38.67 | 8 | 1698 | 675 | 110586918 |
| Prosopagnosia | 43.61 | 38.67 | 6 | 1700 | 94 | 110587499 |
| Hepatitis fulminant | 42.29 | 38.67 | 12 | 1694 | 8548 | 110579045 |
| Aphasia | 39.74 | 38.67 | 19 | 1687 | 58978 | 110528615 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G03HA01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANTIANDROGENS Antiandrogens, plain |
| ATC | G03HB01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANTIANDROGENS Antiandrogens and estrogens |
| MeSH PA | D000726 | Androgen Antagonists |
| MeSH PA | D006727 | Hormone Antagonists |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D003272 | Contraceptive Agents, Male |
| MeSH PA | D012102 | Reproductive Control Agents |
| CHEBI has role | CHEBI:35497 | androgen antagonist |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:59826 | progestin |
| CHEBI has role | CHEBI:176497 | geroprotector |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Androgen receptor | Nuclear hormone receptor | ANTAGONIST | IC50 | 7.43 | WOMBAT-PK | IUPHAR | |||
| Mu-type opioid receptor | GPCR | Ki | 6.05 | DRUG MATRIX | |||||
| Glucocorticoid receptor | Nuclear hormone receptor | IC50 | 7.80 | WOMBAT-PK | |||||
| Progesterone receptor | Nuclear hormone receptor | IC50 | 9.68 | WOMBAT-PK | |||||
| Androgen receptor | Transcription factor | IC50 | 4.74 | CHEMBL | |||||
| Progesterone receptor | Transcription factor | Ki | 8.32 | DRUG MATRIX | |||||
| Adenosine receptor A1 | GPCR | IC50 | 8.30 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000167457 | NUI |
| D01368 | KEGG_DRUG |
| 22054 | RXNORM |
| C0056855 | UMLSCUI |
| CHEBI:50743 | CHEBI |
| CA4 | PDB_CHEM_ID |
| CHEMBL139835 | ChEMBL_ID |
| D017373 | MESH_DESCRIPTOR_UI |
| DB04839 | DRUGBANK_ID |
| 9880 | PUBCHEM_CID |
| 2865 | IUPHAR_LIGAND_ID |
| 4KM2BN5JHF | UNII |
| 003475 | NDDF |
| 004825 | NDDF |
| 126119006 | SNOMEDCT_US |
| 126120000 | SNOMEDCT_US |
| 96370002 | SNOMEDCT_US |
| C0010621 | UMLSCUI |
| 2098-66-0 | SECONDARY_CAS_RN |
| 5284537 | PUBCHEM_CID |
| 2050 | INN_ID |
| D003534 | MESH_DESCRIPTOR_UI |
| E61Q31EK2F | UNII |
| CHEBI:50742 | CHEBI |
| 4KM2BN5JHF | INXIGHT DRUGS |
| E61Q31EK2F | INXIGHT DRUGS |
Pharmaceutical products:
None